A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer
Background: This is a retrospective study to examine the effect of chemotherapy with or without intravenous vitamin C (IVC) on women with advanced triple-negative breast cancer (TNBC). Methods: From 2008 to 2016, a total of 113 patients with pathologically confirmed TNBC at Clifford Hospital were ev...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-02-01
|
| Series: | Integrative Cancer Therapies |
| Online Access: | https://doi.org/10.1177/1534735419895591 |
| _version_ | 1818447267671048192 |
|---|---|
| author | Junwen Ou PhD Xinyu Zhu MS Hongyu Zhang BS Yanping Du MS Pengfei Chen BS Junhua Wang BS Xiufan Peng MS Shuang Bao BS Xinting Zhang MS Tao Zhang BS Clifford L. K. Pang PhD |
| author_facet | Junwen Ou PhD Xinyu Zhu MS Hongyu Zhang BS Yanping Du MS Pengfei Chen BS Junhua Wang BS Xiufan Peng MS Shuang Bao BS Xinting Zhang MS Tao Zhang BS Clifford L. K. Pang PhD |
| author_sort | Junwen Ou PhD |
| collection | DOAJ |
| description | Background: This is a retrospective study to examine the effect of chemotherapy with or without intravenous vitamin C (IVC) on women with advanced triple-negative breast cancer (TNBC). Methods: From 2008 to 2016, a total of 113 patients with pathologically confirmed TNBC at Clifford Hospital were evaluated, and 70 patients were matched and divided into IVC (treatment group) and non-IVC groups (control group). The match was according to age, menopausal status, and metastatic sites. In the control group, 35 patients received gemcitabine and carboplatin. In the treatment group, 35 patients received the same chemotherapy plus IVC. Results: Baseline characteristics were not significantly different between the 2 groups. According to the criteria of RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), enhanced computed tomography scan was compared after 2 cycles of chemotherapy. In the treatment group, 2/35 cases had a complete remission (CR), 15/35 cases had partial remission (PR), and 13/35 cases had stable disease (SD). The response rate was 48.6%. In the control group, there were no CR cases, 14/35 cases had PR, 14/35 cases had SD, and the response rate was 40.0% ( P > .05). The median progression-free survival time and median overall survival time was 7 months (95% confidence interval [CI] =1.5-28.5 months) and 27 months (95% CI = 4-40 months) in the treatment group compared with 4.5 months (95% CI = 1.5-8 months) and 18 months (95% CI = 3-26 months) in the control group ( P < .05). All patients experienced diverse reactions in the gastrointestinal tract and myelosuppression. The incidence of adverse reactions in the treatment group was significantly lower than that of the control group ( P < .05). Conclusion: IVC may have an effect on improving the prognosis of patients with advanced TNBC. |
| first_indexed | 2024-12-14T20:00:54Z |
| format | Article |
| id | doaj.art-d3779d71902347d7ab1d67745b303573 |
| institution | Directory Open Access Journal |
| issn | 1534-7354 1552-695X |
| language | English |
| last_indexed | 2024-12-14T20:00:54Z |
| publishDate | 2020-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Integrative Cancer Therapies |
| spelling | doaj.art-d3779d71902347d7ab1d67745b3035732022-12-21T22:49:09ZengSAGE PublishingIntegrative Cancer Therapies1534-73541552-695X2020-02-011910.1177/1534735419895591A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast CancerJunwen Ou PhD0Xinyu Zhu MS1Hongyu Zhang BS2Yanping Du MS3Pengfei Chen BS4Junhua Wang BS5Xiufan Peng MS6Shuang Bao BS7Xinting Zhang MS8Tao Zhang BS9Clifford L. K. Pang PhD10Clifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaClifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of ChinaBackground: This is a retrospective study to examine the effect of chemotherapy with or without intravenous vitamin C (IVC) on women with advanced triple-negative breast cancer (TNBC). Methods: From 2008 to 2016, a total of 113 patients with pathologically confirmed TNBC at Clifford Hospital were evaluated, and 70 patients were matched and divided into IVC (treatment group) and non-IVC groups (control group). The match was according to age, menopausal status, and metastatic sites. In the control group, 35 patients received gemcitabine and carboplatin. In the treatment group, 35 patients received the same chemotherapy plus IVC. Results: Baseline characteristics were not significantly different between the 2 groups. According to the criteria of RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), enhanced computed tomography scan was compared after 2 cycles of chemotherapy. In the treatment group, 2/35 cases had a complete remission (CR), 15/35 cases had partial remission (PR), and 13/35 cases had stable disease (SD). The response rate was 48.6%. In the control group, there were no CR cases, 14/35 cases had PR, 14/35 cases had SD, and the response rate was 40.0% ( P > .05). The median progression-free survival time and median overall survival time was 7 months (95% confidence interval [CI] =1.5-28.5 months) and 27 months (95% CI = 4-40 months) in the treatment group compared with 4.5 months (95% CI = 1.5-8 months) and 18 months (95% CI = 3-26 months) in the control group ( P < .05). All patients experienced diverse reactions in the gastrointestinal tract and myelosuppression. The incidence of adverse reactions in the treatment group was significantly lower than that of the control group ( P < .05). Conclusion: IVC may have an effect on improving the prognosis of patients with advanced TNBC.https://doi.org/10.1177/1534735419895591 |
| spellingShingle | Junwen Ou PhD Xinyu Zhu MS Hongyu Zhang BS Yanping Du MS Pengfei Chen BS Junhua Wang BS Xiufan Peng MS Shuang Bao BS Xinting Zhang MS Tao Zhang BS Clifford L. K. Pang PhD A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer Integrative Cancer Therapies |
| title | A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer |
| title_full | A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer |
| title_fullStr | A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer |
| title_full_unstemmed | A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer |
| title_short | A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer |
| title_sort | retrospective study of gemcitabine and carboplatin with or without intravenous vitamin c on patients with advanced triple negative breast cancer |
| url | https://doi.org/10.1177/1534735419895591 |
| work_keys_str_mv | AT junwenouphd aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT xinyuzhums aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT hongyuzhangbs aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT yanpingdums aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT pengfeichenbs aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT junhuawangbs aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT xiufanpengms aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT shuangbaobs aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT xintingzhangms aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT taozhangbs aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT cliffordlkpangphd aretrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT junwenouphd retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT xinyuzhums retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT hongyuzhangbs retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT yanpingdums retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT pengfeichenbs retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT junhuawangbs retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT xiufanpengms retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT shuangbaobs retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT xintingzhangms retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT taozhangbs retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer AT cliffordlkpangphd retrospectivestudyofgemcitabineandcarboplatinwithorwithoutintravenousvitaminconpatientswithadvancedtriplenegativebreastcancer |